Embolism and Thrombosis Clinical Trial
Official title:
Screening for Occult Malignancy Using 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG PET/CT) in Patients With Unprovoked Venous Thromboembolism
Venous thromboembolism (VTE) can be the earliest sign of cancer. Identifying occult cancers at the time of VTE diagnosis may lead to significant improvement of patients' care. This is also an upmost issue for patients who want to know if an underlying cancer might have triggered the VTE. An individual patient-level data meta-analysis (IPDMA) supports extensive screening strategies for occult cancer especially based on FDG PET/CT, and suggests that the best target population for cancer screening would be patients with unprovoked VTE older than 50 years of age (6.7% in patients aged 50 years or more vs. 1.0% in patients of less than 50 years (OR: 7.1, 95% CI: 3.1 to 16%).
The identification of subgroups of patients at high risk of cancer might enable more efficient screening strategies for early detection of cancer. Venous thromboembolism (VTE) can be the first manifestation of an occult cancer. All tumor sites may be involved. In an individual patient-level data meta-analysis (IPDMA), it was reported a 1-year prevalence of occult cancer of 5.2% (95%CI 4.1-6.5) among patients presenting with unprovoked VTE. Two recent multicenter randomized controlled trials (e.g. SOME (Canada) and MVTEP (France) trials) failed to demonstrate that extensive cancer screening strategies diagnosed more cancers, more early stage tumors, or improved cancer-related mortality in comparison with a more limited screening strategy. However, the main limitation of these studies was the twice lower than expected overall incidence of occult cancer diagnosis in unselected patients with unprovoked VTE, which limited the statistical power. In the IPDMA, it was also reported that the 1-year period prevalence of occult cancer was 7-fold higher in patients aged ≥ 50 (6.8%; 95%CI 5.6-8.3) as compared with those < 50 years (1.0%; 95%CI 0.5-2.3). Moreover, in the MVTEP trial, the incidence of missed cancers over a 2-years follow-up period was significantly lower in patients randomized to a 18F-Fluorodeoxyglucose Positron Emission/Computed Tomography (FDG-PET/CT) screening strategy. Thus, the most promising diagnostic modality for occult cancer screening seems to be FDG-PET/CT. FDG-PET/CT which allows a one-stop whole-body imaging, is routinely used for the diagnosis, staging and restaging of various cancers. The MVTEP2 Trial seeks to determine if among higher risk patients (≥ 50 year-old) with a first unprovoked VTE, a cancer screening strategy including a FDG-PET/CT decreases the number of missed occult cancers detected over a 1-year follow-up period as compared with a limited screening alone. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00216866 -
The Catheter Study: Central Venous Catheter Survival in Cancer Patients Using Low Molecular Weight Heparin (Dalteparin) for the Treatment of Deep Vein Thrombosis
|
Phase 2 | |
Recruiting |
NCT05907564 -
Aventus Thrombectomy System Pulmonary Embolism Clinical Study
|
N/A | |
Completed |
NCT05128591 -
A Study to Compare Pharmacokinetic Parameters and Safety Profiles Between AD-109 and AD-1091
|
Phase 1 | |
Completed |
NCT00670540 -
Epidemiology of Thromboembolism Disease: A Cohort Study
|
N/A | |
Recruiting |
NCT04263038 -
Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism
|
Phase 4 | |
Recruiting |
NCT04388657 -
COVID-19, bLOod Coagulation and Thrombosis
|
||
Completed |
NCT04439383 -
Risk Stratification for Venous Thromboembolism in Hospitalized Medical Patients
|
||
Completed |
NCT01897103 -
Platelet Activity in Vascular Surgery for Thrombosis and Bleeding
|
N/A | |
Recruiting |
NCT04657120 -
Safety and Efficiency of the YEARS Algorithm Versus Computed Tomography Pulmonary Angiography Alone for Suspected Pulmonary Embolism in Patients With Malignancy
|
N/A | |
Completed |
NCT02720328 -
Prevalence and Causes of Preventable and Serious Adverse Drug Reactions Related to the Use of Oral Anticoagulants
|
Phase 4 | |
Completed |
NCT01203098 -
A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty
|
Phase 2 | |
Completed |
NCT00830570 -
The Clinical and Economic Impact of Pharmacogenomic Testing of Warfarin Therapy in Typical Community Practice Settings
|
N/A | |
Recruiting |
NCT05568966 -
Collection of Blood Samples for New Diagnostic Devices 2
|
N/A | |
Not yet recruiting |
NCT06209892 -
Prolonged Anticoagulation Therapy on the Prognosis of Patients With Left Ventricular Thrombosis
|
N/A | |
Completed |
NCT01086215 -
Registry of AngioJet Use in the Peripheral Vascular System
|
N/A | |
Completed |
NCT02996851 -
Traumatic Intracranial Hemorrhage in Users of Oral Antithrombotic Drugs
|
N/A | |
Completed |
NCT00119457 -
Factor IX Inhibition in Thrombosis Prevention (The FIXIT Trial)
|
Phase 2 | |
Recruiting |
NCT05853796 -
Observational Dutch Young Symptomatic StrokE studY - nEXT
|
||
Terminated |
NCT02610608 -
Medical Assistance for the Procreation and Risk of Thrombosis.
|
||
Completed |
NCT04368377 -
Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19
|
Phase 2 |